Aptorum Group (NASDAQ:APM) is a dynamic biopharmaceutical company dedicated to developing and commercializing a diverse range of innovative therapeutic and diagnostic technologies targeting unmet medical needs. With a strategic focus on infectious diseases and oncology, among other fields, Aptorum is actively engaged in advancing its pipeline through rigorous research and development efforts. They are committed to leveraging cutting-edge science and technology to provide new solutions that can significantly improve patient outcomes and quality of life. Their objective is to lead the way in discovering and developing novel therapeutics and diagnostics that address the critical challenges faced by patients around the globe.